Lung cancer as a paradigm for precision oncology in solid tumours (Q39449763)

12 September 2017

title

Lung cancer as a paradigm for precision oncology in solid tumours (English)

1 reference

12 September 2017

author

Sabine Merkelbach-Bruse

series ordinal

2

object named as

Sabine Merkelbach-Bruse

0 references

author name string

Simon Schallenberg

series ordinal

1

1 reference

12 September 2017

Reinhard Buettner

series ordinal

3

1 reference

12 September 2017

publication date

20 July 2017

1 reference

12 September 2017

1 reference

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

New immunohistochemical markers in the differential diagnosisof nonsmall cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

A genomics-based classification of human lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Characterization of ROS1 cDNA from a human glioblastoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Expression and rearrangement of the ROS1 gene in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Molecular pathways: ROS1 fusion proteins in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Comprehensive molecular profiling of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Organization of the human hepatocyte growth factor-encoding gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Ethnic differences and functional analysis of MET mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Somatic mutations lead to an oncogenic deletion of met in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

KIF5B-RET fusions in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

A patient with lung adenocarcinoma and RET fusion treated with vandetanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Translational implications of tumor heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Activation of RAS family members confers resistance to ROS1 targeting drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

[Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Anchored multiplex PCR for targeted next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2183-2

HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin

21 January 2018

1 reference

12 December 2020

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer

1 reference

12 December 2020

Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

12 December 2020

High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer

1 reference

12 December 2020

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations

1 reference

12 December 2020

10.1007/S00428-017-2183-2

Identifiers

DOI

1 reference

12 September 2017

1 reference